Acute Effects of Zynamite® S in Cognitive Function and Mood
NCT07126717, Not applicable, Completed, Nektium Pharma SL
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Acute Effects of Zynamite® S in Cognitive Function and Mood | ClinicalTrials.gov |
| NCT number | NCT07126717 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 88 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Nektium Pharma SL | ClinicalTrials.gov |
| Conditions | Cognitive Performance, Mood | ClinicalTrials.gov |
| Interventions | Placebo, Zynamite® S | ClinicalTrials.gov |
| First posted | 2025-08-17 | ClinicalTrials.gov |
| Last updated | 2025-08-17 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes in Trail Making Test (TMT) Score | At baseline (30 minutes before supplement intake), at 30 minutes, 3 hours, and 5 hours after supplement intake. | Changes in the Trail Making Test (TMT) score will be used to evaluate executive functions between placeobo and Zynamite® S groups. This test is divided into two parts wtih 25 items each: Part A (TMT-A), which evaluates psychomotor attention and speed and involves connecting consecutively numbered circles, and Part B (TMT-B), which requires connecting alternating circles of letters and numbers and is used to measure executive function. A longer time taken to complete the test is interpreted as poorer performance. | ClinicalTrials.gov |
| Primary | Changes in Digit symbol substitution test (DSST) Score | At baseline (30 minutes before supplement intake), at 30 minutes, 3 hours, and 5 hours after supplement intake. | Changes in the Digit symbol substitution test (DSST) will be employed to compare performance on processing speed, attention, and working memory between placebo and Zynamite® S groups. DSST is a paper-and-pencil cognitive test presented on a single sheet of paper, requiring the subject to match symbols with numbers according to a key located at the top of the page. The subject copies the symbol into spaces beneath a row of numbers. The score is based on the number of correct symbols the participant manages to substitute within 90 s. | ClinicalTrials.gov |
| Primary | Changes in Stroop Color and Word & Stroop Interference Score | At baseline (30 minutes before supplement intake), at 30 minutes, 3 hours, and 5 hours after supplement intake. | Changes in the Stroop Color and Word Test and Stroop Interefernce Test will be used to assess cognitive functions, such as selective attention and cognitive flexibility between placebo and Zynamite® S groups. The Stroop Color and Word Test consists on three 45-second tasks. First, the participants read color words printed in black ink (the 'P' score). Next, they name the ink color of "XXXX" symbols (the 'C' score). In the final interference stage, the participant must state the ink color of a word that is printed in a conflicting color, such as the word "BLUE" printed in red ink (the 'PC' score). These three scores are then used to calculate a final T score of interference, where a higher score indicates better performance and attention control. | ClinicalTrials.gov |
| Secondary | Changes in Profile of Mood States (POMS) Score | At baseline (30 minutes before supplement intake), at 30 minutes, 3 hours, and 5 hours after supplement intake. | Changes on the Profile of Mood States (POMS) score will be used to evaluate mood and well-being between placebo and Zynamite® S groups. Participants will complete the Spanish short version of the POMS 65-item questionnaire, which includes a total of 6 subscales: tension (score range 0 to 36), depression (score range 0 to 60), anger (score range 0 to 48), fatigue (score range 0 to 28), vigor (score range 0 to 32), and confusion (score range 0 to 28), as well as a total mood disturbance score (score range -32 to 200). The total mood disturbance score is calculated by summing the five negative subscale scores (tension, depression, anger, fatigue, and confusion) and subtracting the vigor score. Higher scores for the total mood disturbance indicate a greater degree of mood disturbance. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 12
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 25064341 | BACKGROUND | PubMed |
| 28410265 | BACKGROUND | PubMed |
| 30013719 | BACKGROUND | PubMed |
| 32473365 | BACKGROUND | PubMed |
| 32717999 | BACKGROUND | PubMed |
| 33424383 | BACKGROUND | PubMed |
| 33641782 | BACKGROUND | PubMed |
| 33802176 | BACKGROUND | PubMed |
| 36014874 | BACKGROUND | PubMed |
| 36117559 | BACKGROUND | PubMed |
| 39942566 | BACKGROUND | PubMed |
| 40284006 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)